Stock Alert: Kiniksa Shares Up 31% In Premarket On Positive Data From Phase 3 Trial Of Rilonacept

Shares of Kiniksa Pharmaceuticals Ltd. (KNSA) are soaring over 31% in pre-market today, after the company reported positive data from RHAPSODY, a pivotal Phase 3 trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signaling, in recurrent pericarditis.

from RTT - Before the Bell https://ift.tt/3eIz2bx
via IFTTT